Linolacort Hydro (Hydrocortisone)

Hydrocortisone binds to glucocorticoid receptors inside skin cells, forming a complex that alters gene transcription. This leads to decreased production of pro‑inflammatory cytokines and increased synthesis of anti‑inflammatory proteins, thereby limiting edema, erythema and immune cell activity at the site of application.

The appropriate amount and frequency of Linolacort Hydro are determined by the prescribing healthcare professional based on the specific condition, severity, patient age and treatment area. Patients should follow the prescriber’s instructions and not exceed the recommended application regimen.

Safety of topical hydrocortisone in pregnancy or lactation has not been definitively established. Healthcare providers usually weigh potential benefits against risks and may recommend the lowest effective potency for the shortest duration. Patients should discuss their situation with a qualified clinician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Linolacort Hydro contains hydrocortisone, a low‑ to medium‑potency corticosteroid, making it suitable for mild to moderate skin inflammation. Stronger steroids such as betamethasone or clobetasol provide greater potency but carry higher risk of side effects. Choice depends on disease severity, treatment area and physician judgment.

Store Linolacort Hydro at room temperature below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight. Do not freeze the preparation, and ensure the container is tightly closed when not in use.

Clean and gently dry the affected skin area before use. Apply a thin layer of Linolacort Hydro to the lesion and rub gently until it disappears. Wash hands after application unless the hands are being treated. Follow the prescriber’s frequency and duration instructions.

Serious risks include skin atrophy, striae formation, hypopigmentation, secondary infections, and systemic adrenal suppression when large surface areas are treated for prolonged periods. Patients should report any unusual thinning of the skin, persistent redness, or signs of infection to their healthcare provider promptly.

Linolacort Hydro should be avoided in individuals with known hypersensitivity to hydrocortisone or any formulation excipients, on untreated bacterial, viral or fungal skin infections, and on extensive broken skin unless directed by a physician. Caution is also advised for infants, young children and patients with systemic steroid therapy.